Yes, semaglutide is prescription only. It is not available over the counter in any country, including the United States, United Kingdom, and Australia. Every brand of semaglutide requires a licensed healthcare provider to evaluate you, determine you’re a candidate, and write a prescription before you can obtain it.
Brand Names and What They Treat
Semaglutide is sold under three main brand names, each approved for different uses. Ozempic is an injectable prescribed for adults with type 2 diabetes to improve blood sugar control and reduce the risk of heart attack, stroke, and cardiovascular death. Rybelsus is an oral tablet version approved for the same type 2 diabetes indications. Wegovy is an injectable prescribed specifically for chronic weight management.
Wegovy’s approval covers adults with a BMI of 30 or greater, or a BMI of 27 or greater if they also have at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. It’s also approved for children aged 12 and older whose BMI falls at or above the 95th percentile for their age and sex. All three brands are meant to be used alongside diet and exercise changes, not as standalone treatments.
Why It Requires a Prescription
Semaglutide carries real medical risks that need professional screening before use. The most common side effects are gastrointestinal: nausea, vomiting, and diarrhea, which tend to be more pronounced in women, people with higher body weight, and middle-aged adults. Beyond those, the drug carries a boxed warning about thyroid tumors. A large analysis of the French national health database found that people taking this class of drug for one to three years had a 58% higher risk of thyroid cancer overall and a 78% higher risk of medullary thyroid cancer specifically. Anyone with a personal or family history of medullary thyroid cancer is not eligible for the medication.
There’s also a modestly increased risk of gallstones. A review of 113 trials found a 30% higher likelihood of developing them. Long-term data on pancreatitis risk has been more reassuring, with analyses of trials lasting over a year showing no statistically significant increase, but doctors still monitor for it.
These risks are why a prescriber needs to review your medical history, check for contraindications, and set up appropriate monitoring before starting treatment. That typically includes blood sugar testing (an A1C test at least twice a year for diabetes patients), kidney function checks through blood or urine tests, and eye exams if you have a history of diabetic retinopathy.
What the Prescription Process Looks Like
Getting a prescription for semaglutide starts with a visit to a healthcare provider, either in person or through a telehealth platform. Your provider will review your weight history, BMI, existing health conditions, and current medications. If you’re seeking Wegovy for weight loss, you’ll need to meet the BMI thresholds described above. For Ozempic or Rybelsus, you’ll need a type 2 diabetes diagnosis.
Once prescribed, the medication follows a gradual dose increase (called titration) over several weeks. This slow ramp-up is designed to reduce gastrointestinal side effects. Your provider will schedule follow-up visits to check your response, adjust dosing, and run any necessary lab work.
Insurance Often Adds Another Layer
Even with a valid prescription, many insurance plans require prior authorization before they’ll cover semaglutide, particularly Wegovy. This means your doctor’s office submits documentation proving you meet specific clinical criteria. For example, Maryland Medicaid requires a BMI of 27 or higher with documented cardiovascular disease, a recent height and weight measurement within the last 90 days, and confirmation that the prescriber has screened for all contraindications and boxed warnings. Approvals are typically granted in six-month blocks, with renewal requiring continued documentation.
Private insurers have their own criteria, and some don’t cover Wegovy for weight loss at all. This gap in coverage is one reason some people look for alternatives outside the traditional pharmacy system.
Risks of Compounded and Unregulated Versions
The high cost and limited insurance coverage of brand-name semaglutide has fueled a market of compounded versions, some of which are sold through online clinics or social media ads. The FDA has raised serious concerns about these products. Compounded drugs do not undergo FDA review for safety, effectiveness, or quality before they reach patients.
Several specific problems have emerged. Some compounded injectables have arrived warm or without adequate cold packs, which degrades the medication. The FDA has identified fraudulent products with fake pharmacy names on the labels, and in some cases, labels listing pharmacies that confirmed they never made those products. Dosing errors have been a particular danger: the agency has received multiple reports of hospitalizations tied to patients measuring incorrect doses from compounded vials, or being prescribed doses higher than what’s in the approved labeling.
Some compounders have also used semaglutide salt forms, such as semaglutide sodium or semaglutide acetate. These are chemically different from the active ingredient in approved drugs, and the FDA has stated it has no information confirming they behave the same way in the body. The agency is not aware of any lawful basis for using these salt forms in compounding.
Australia’s drug regulator has taken similar enforcement action, pursuing compounding pharmacies that advertised prescription-only weight loss products directly to consumers and warning social media influencers against promoting prescription medications. The consistent message across regulators is clear: semaglutide in any form is a prescription medication, and obtaining it outside that system introduces risks that aren’t present with properly dispensed, FDA-approved products.